SES and AXESS Networks to Enable Smart Mining with O3b mPOWER
28.7.2022 09:50:00 EEST | Business Wire | Press release
SES and AXESS Networks (AXESS), a leading provider of satellite connectivity solutions, are accelerating digital transition of the mining industry with SES’s second-generation medium earth orbit (MEO) system O3b mPOWER, the two companies announced today. Under this multi-year, multi-million agreement, the mining sector users will be able to benefit from the cutting-edge low-latency Onshore Energy & Mining mPOWERED connectivity service.
SES’s Onshore Energy & Mining mPOWERED service will provide the highest throughput available from a satellite system and deliver dedicated and carrier-grade networks to AXESS’ customers reliably regardless of their remote locations. O3b mPOWER can deliver up to multiple gigabits per second per site, enabling AXESS’ customers to accelerate the digitalisation of their operations and sites globally, boosting profitability through access to new applications and efficiency, as well as improving staff safety and welfare. SES’s second-generation MEO connectivity service also brings the Cloud closer to the end customers and can enable edge computing to support the use of 5G and IoT in the mining industry.
Simon GattySaunt, Vice President of Networks Sales, Europe, at SES, said, “Transition towards smart mining is already turbocharging profits, and revolutionising industry’s environmental and societal impact. We are proud of the success our partnership with AXESS has already had in facilitating this change, thanks to our multi-orbit GEO and MEO network, and are excited to further accelerate it with the O3b mPOWER service.”
Guido Neumann, President AXESS EMEA said, “This agreement builds on a long and successful relationship with SES, which has helped us to provide our customers with the best-in-class, reliable and resilient connectivity for their operations. As we are seeing a considerable uptake in demand for the carrier-grade solutions globally, but especially in the EMEA and APAC region, we are honoured to play an active role in scaling the digital transition in the mining sector through introducing O3b mPOWER and the Onshore Energy & Mining mPOWERED service.”
Follow us on:
Twitter | Facebook | YouTube | LinkedIn | Instagram
Read our Blogs >
Visit the Media Gallery >
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over ~8,200 channels and has an unparalleled reach of 366 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com
About AXESS Networks
AXESS Networks (AXESS) is a global leader in satellite-based solutions that manages the entire satellite communications value chain with engineering solutions tailored to its customers’ requirements. AXESS was founded in 2019 via the merger of CETel and Axesat, two well-established companies in Europe and Latin America. AXESS operates and owns Teleports in Germany, Colombia, Mexico, Peru, Saudi Arabia and the United Arab Emirates (UAE). It provides turnkey solutions for the individual requirements of its clients from a broad range of industries: Corporate, Energy, Maritime, Telcos, Government, Humanitarian Services and Media. More than 200 AXESS employees serve over 800 clients in 50 countries with deep market understanding. AXESS was awarded as the Independent Teleport Operator of the Year by the WTA (World Teleport Association) in 2021. Further information is available at: www.axessnet.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220727006150/en/
Contact information
Suzanne Ong
External Communications, SES
+352 710 725 500
suzanne.ong@ses.com
Corinne Effinger
Communications Manager, AXESS EMEA
+49 2295 90878 38
corinne.effinger@axessnet.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
